Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;15(4):524-528.
doi: 10.5217/ir.2017.15.4.524. Epub 2017 Oct 23.

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy

Affiliations

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy

Way-Seah Lee et al. Intest Res. 2017 Oct.

Abstract

Anti-tumor necrosis factor (anti-TNF) is highly effective in inflammatory bowel disease (IBD); however, it is associated with an increased risk of infections, particularly in older adults. We reviewed 349 patients with IBD, who were observed over a 12-month period, 74 of whom had received anti-TNF therapy (71 patients were aged <60 years and 3 were aged ≥60 years). All the 3 older patients developed serious infectious complications after receiving anti-TNFs, although all of them were also on concomitant immunosuppressive therapy. One patient developed disseminated tuberculosis, another patient developed cholera diarrhea followed by nosocomial pneumonia, while the third patient developed multiple opportunistic infections (Pneumocystis pneumonia, cryptococcal septicemia and meningitis, Klebsiella septicemia). All 3 patients died within 1 year from the onset of the infection(s). We recommend that anti-TNF, especially when combined with other immunosuppressive therapy, should be used with extreme caution in older adult patients with IBD.

Keywords: Anti-tumor necrosis factor; Elderly patients; Serious infections.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None.

Figures

Fig. 1
Fig. 1. Cross-sectional view of the CT image showing pneumonia of the right lung and multiple alveolar consolidations, consistent with the diagnosis of Pneumocystis jiroveci pneumonia (case 1).
Fig. 2
Fig. 2. Endoscopic image showing recurrence of CD (case 2).
Fig. 3
Fig. 3. CT image of the abdomen showing disseminated micro-abscesses of the liver and spleen (arrows) (case 2).

References

    1. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62. - PubMed
    1. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030. - PubMed
    1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549. - PubMed
    1. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239. - PMC - PubMed
    1. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250. - PubMed

LinkOut - more resources